Treprostinil etkileşimleri

…fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.8 , 5.9) ] • Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium and misoprostol, other prostaglandins, or any components of the drug product [see Warnings and Precautions (5.8 , 5.10) ] • Pregnancy ( 4 ) (Diklofenak ve misoprostol etiketi, Kontrendikasyonlar)

Ketorolac tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of uterine hemorrhage. (Ketorolak etiketi, Kontrendikasyonlar)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (Latanoprost etiketi, İlaç etkileşimleri)

Hypotension Adenosine injection is a potent peripheral vasodilator and can induce significant hypotension. (Adenozin etiketi, Uyarılar ve önlemler)

Nonetheless, caution, as with any other peripheral vasodilator, should be exercised when administering amlodipine, particularly in patients with severe aortic stenosis. (Amlodipin ve valsartan etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Atenolol etiketi, İlaç etkileşimleri)

Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (Atenolol ve klortalidon etiketi, İlaç etkileşimleri)

When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (Avanafil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

• Co-administration with Other Vasodilators or Negative Chronotropic Agents : Use with caution due to additive pharmacodynamic effects. (Deksmedetomidin etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Diflunisal etiketi, Uyarılar)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Diklofenak etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Epoprostenol etiketi, İlaç etkileşimleri)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Etodolak etiketi, Uyarılar)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Fenoprofen etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Flurbiprofen etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Indomethacin Coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis. (Furosemid etiketi, İlaç etkileşimleri)

Effect of Other Drugs on Treprostinil Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both C max and AUC) to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Renal Toxicity and Hyperkalemia Renal Toxicity Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Hidrokodon ve ibuprofen etiketi, Uyarılar)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (İbuprofen etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (İbuprofen ve famotidin etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (İndometazin etiketi, Uyarılar ve önlemler)

Drug Interactions The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators. (İzosorbid dinitrat etiketi, İlaç etkileşimleri)

The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators. (İzosorbid mononitrat etiketi, İlaç etkileşimleri)

Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (Kaptopril etiketi, Önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. (Ketoprofen etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Mefenamik asit etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Meloksikam etiketi, Uyarılar ve önlemler)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (Metilergometrin etiketi, İlaç etkileşimleri)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Nabumeton etiketi, Uyarılar)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Naproksen etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Naproksen ve esomeprazol etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Nifedipine is a vasodilator, and co-administration of other drugs affecting blood pressure may result in pharmacodynamic interactions. (Nifedipin etiketi, İlaç etkileşimleri)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Oksaprozin etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Parasetamol ve ibuprofen etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Piroksikam etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Salsalat etiketi, Uyarılar)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Selekoksib etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

Blood Pressure Decreases Patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be sensitive to the actions of vasodilators, including SILDENAFIL ORAL FILM. (Sildenafil etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion.In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. (Sulindak etiketi, Uyarılar)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Sumatriptan ve naproksen etiketi, Uyarılar ve önlemler)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (Tadalafil etiketi, Uyarılar ve önlemler)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (Tolmetin etiketi, Uyarılar)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (Treprostinil etiketi, Uyarılar ve önlemler)

When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (Vardenafil etiketi, Uyarılar ve önlemler)

The pharmacokinetics of R- and S- warfarin and the international normalized ratio (INR) in healthy subjects given a single 25 mg dose of warfarin were unaffected by continuous subcutaneous infusion of treprostinil at an infusion rate of 10 ng/kg/min. (Treprostinil etiketi, İlaç etkileşimleri)

Antihypertensive Agents Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers) will usually have an additive effect on lowering blood pressure. (Verapamil etiketi, İlaç etkileşimleri)

Drugs antagonizing pressor effects of epinephrine α-blockers, such as phentolamine Vasodilators, such as nitrates Diuretics Antihypertensives Ergot alkaloids Drugs potentiating pressor effects of epinephrine • Sympathomimetics • β-blockers, such as propranolol • Tricyclic anti-depressants • Monoamine oxidase (MAO) inhibitors • Catechol-O-methyl transferase (COMT)… (Adrenalin etiketi, İlaç etkileşimleri)

Phosphodiesterase-5 (PDE5) Inhibitors: PDE5-inhibitors are also vasodilators. (Alfuzosin etiketi, Uyarılar ve önlemler)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (Treprostinil etiketi, Uyarılar ve önlemler)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (Treprostinil etiketi, Uyarılar ve önlemler)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (Treprostinil etiketi, Uyarılar ve önlemler)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (Treprostinil etiketi, Uyarılar ve önlemler)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (Treprostinil etiketi, İlaç etkileşimleri)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (Treprostinil etiketi, Uyarılar ve önlemler)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (Treprostinil etiketi, Uyarılar ve önlemler)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (Treprostinil etiketi, İlaç etkileşimleri)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (Treprostinil etiketi, İlaç etkileşimleri)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (Treprostinil etiketi, Uyarılar ve önlemler)

Alpha-adrenergic antagonists and PDE-5 inhibitors are both vasodilators that can lower blood pressure. (Dutasterid ve tamsulosin etiketi, Uyarılar ve önlemler)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (Treprostinil etiketi, İlaç etkileşimleri)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (Treprostinil etiketi, İlaç etkileşimleri)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (Treprostinil etiketi, Uyarılar ve önlemler)

Post injury arterial injection of vasodilators and/or arterial infusion of parenteral fluids are generally regarded to be of no value in altering outcome. (Metoheksital etiketi, Uyarılar)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (Treprostinil etiketi, Uyarılar ve önlemler)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (Treprostinil etiketi, İlaç etkileşimleri)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (Treprostinil etiketi, Uyarılar ve önlemler)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (Treprostinil etiketi, İlaç etkileşimleri)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (Treprostinil etiketi, İlaç etkileşimleri)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (Potasyum klorür etiketi, İlaç etkileşimleri)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (Silodosin etiketi, Uyarılar ve önlemler)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (Tamsulosin etiketi, Uyarılar ve önlemler)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (Treprostinil etiketi, İlaç etkileşimleri)